Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Pavan_Cheruvu
|
| gptkbp:focusesOn |
gene therapy
neurological diseases |
| gptkbp:formerName |
gptkb:Axovant_Gene_Therapies
|
| gptkbp:foundedBy |
gptkb:Vivek_Ramaswamy
|
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Axovant Sciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableEvent |
intepirdine Phase III trial failure in 2017
|
| gptkbp:notableProduct |
gptkb:intepirdine
gptkb:nelotanserin |
| gptkbp:parentCompany |
gptkb:Roivant_Sciences
|
| gptkbp:renamed |
gptkb:Sio_Gene_Therapies
|
| gptkbp:stockSymbol |
gptkb:AXON
|
| gptkbp:website |
https://www.siogtx.com/
|
| gptkbp:bfsParent |
gptkb:David_Hung
gptkb:Roivant_Sciences_Ltd. |
| gptkbp:bfsLayer |
6
|